{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:38:41Z","timestamp":1792226321790,"version":"4.4.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ncl.2022.05.001","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T03:22:14Z","timestamp":1666063334000},"page":"123-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Management of Psychiatric Symptoms in Dementia"],"prefix":"10.1016","volume":"41","author":[{"given":"Yavuz","family":"Ayhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selam A.","family":"Yoseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2022.05.001_bib1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","article-title":"The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: systematic review and meta-analysis","volume":"190","author":"Zhao","year":"2016","journal-title":"J\u00a0Affect Disord"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.001_bib2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/gps.5556","article-title":"Prevalence of depression, anxiety, and apathy symptoms across dementia stages: A systematic review and meta-analysis","volume":"36","author":"Leung","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"issue":"13","key":"10.1016\/j.ncl.2022.05.001_bib3","doi-asserted-by":"crossref","first-page":"e1276","DOI":"10.1212\/WNL.0000000000012598","article-title":"Neuropsychiatric and cognitive symptoms across the Alzheimer disease clinical spectrum: cross-sectional and longitudinal associations","volume":"97","author":"Eikelboom","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1017\/S1041610217001880","article-title":"Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria","volume":"30","author":"Ismail","year":"2018","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib5","doi-asserted-by":"crossref","first-page":"e12016","DOI":"10.1002\/trc2.12016","article-title":"Agitation and impulsivity in mid and late life as possible risk markers for incident dementia","volume":"6","author":"Bateman","year":"2020","journal-title":"Alzheimers Dement (N Y)."},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.psc.2017.10.010","article-title":"Managing behavioral and psychological symptoms of dementia","volume":"41","author":"Gerlach","year":"2018","journal-title":"Psychiatr Clin North Am"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.001_bib7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","article-title":"Neuropsychiatric symptoms as predictors of progression to severe Alzheimer\u2019s dementia and death: the Cache County Dementia Progression Study","volume":"172","author":"Peters","year":"2015","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1017\/S1041610216001654","article-title":"Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis","volume":"29","author":"Toot","year":"2017","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/psyg.12393","article-title":"Factors influencing hospital admission among patients with autopsy-confirmed dementia","volume":"19","author":"Matsuoka","year":"2019","journal-title":"Psychogeriatrics"},{"issue":"8","key":"10.1016\/j.ncl.2022.05.001_bib10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1017\/S1041610217002630","article-title":"Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer\u2019s disease","volume":"30","author":"Liu","year":"2018","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13561-021-00333-z","article-title":"Which factors increase informal care hours and societal costs among caregivers of people with dementia? A systematic review of Resource Utilization in Dementia (RUD)","volume":"11","author":"Angeles","year":"2021","journal-title":"Health Econ Rev"},{"key":"10.1016\/j.ncl.2022.05.001_bib12","first-page":"1","article-title":"Time to invest in prevention and better care of behaviors and psychological symptoms associated with dementia","volume":"31","author":"Burley","year":"2020","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mpr.1414","article-title":"Instruments to measure behavioural and psychological symptoms of dementia","volume":"23","author":"van der Linde","year":"2014","journal-title":"Int J Methods Psychiatr Res"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0891988719882102","article-title":"The neuropsychiatric inventory: development and applications","volume":"33","author":"Cummings","year":"2020","journal-title":"J\u00a0Geriatr Psychiatry Neurol"},{"issue":"1\u20132","key":"10.1016\/j.ncl.2022.05.001_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000357839","article-title":"The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review","volume":"38","author":"Reisberg","year":"2014","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"12","key":"10.1016\/j.ncl.2022.05.001_bib16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jagp.2015.10.001","article-title":"Common sense: addressed to geriatric psychiatrists on the subject of behavioral and psychological symptoms of dementia","volume":"23","author":"Kales","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1176\/appi.neuropsych.18090201","article-title":"Ages at onset of anxiety and depressive disorders in parkinson\u2019s disease","volume":"31","author":"Seritan","year":"2019","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"issue":"Pt 9","key":"10.1016\/j.ncl.2022.05.001_bib18","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib19","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jgs.12730","article-title":"Detroit expert panel on assessment and management of neuropsychiatric symptoms of dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel","volume":"62","author":"Kales","year":"2014","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jagp.2017.05.015","article-title":"Targeted interdisciplinary model for evaluation and treatment of neuropsychiatric symptoms: A cluster randomized controlled trial","volume":"26","author":"Lichtwarck","year":"2018","journal-title":"Am J Geriatr Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2022.05.001_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ggi.13037","article-title":"Predictors of non-pharmacological intervention effect on cognitive function and behavioral and psychological symptoms of older people with dementia","volume":"17","author":"Hsu","year":"2017","journal-title":"Geriatr Gerontol Int"},{"issue":"12","key":"10.1016\/j.ncl.2022.05.001_bib22","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jagp.2015.07.001","article-title":"Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004-2013","volume":"23","author":"Vasudev","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib23","first-page":"719","article-title":"Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer\u2019s disease: a meta-analysis","volume":"3","author":"Campbell","year":"2008","journal-title":"Clin Interv Aging"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3233\/JAD-170424","article-title":"Memantine for Alzheimer\u2019s disease: an updated systematic review and meta-analysis","volume":"60","author":"Kishi","year":"2017","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.001_bib25","doi-asserted-by":"crossref","first-page":"863.e1","DOI":"10.1016\/j.jamda.2016.05.015","article-title":"Combination therapy showed limited superiority over monotherapy for Alzheimer disease: a meta-analysis of 14 randomized trials","volume":"17","author":"Tsoi","year":"2016","journal-title":"J\u00a0Am Med Dir Assoc"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib26","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3233\/JAD-210588","article-title":"Depressive symptoms imputed across the life course are associated with cognitive impairment and cognitive decline","volume":"83","author":"Brenowitz","year":"2021","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41398-021-01269-y","article-title":"Late-life depression and increased risk of dementia: a longitudinal cohort study","volume":"11","author":"Ly","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.ncl.2022.05.001_bib28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jad.2020.12.195","article-title":"Risk of incident dementia varies with different onset and courses of depression","volume":"282","author":"Lee","year":"2021","journal-title":"J\u00a0Affect Disord"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2990.2008.00997.x","article-title":"The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer\u2019s disease. A precocious onset?","volume":"35","author":"Grinberg","year":"2009","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.001_bib30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/gps.5470","article-title":"Mid to late-life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer\u2019s disease pathology at death","volume":"36","author":"Robinson","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/jnnp-2020-324266","article-title":"Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson\u2019s disease: a cross-sectional study","volume":"92","author":"Kazmi","year":"2021","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/psyg.12391","article-title":"Cognitive behavioural therapy can be effective in treating anxiety and depression in persons with dementia: a systematic review","volume":"19","author":"Tay","year":"2019","journal-title":"Psychogeriatrics"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib33","first-page":"CD009125","article-title":"Psychological treatments for depression and anxiety in dementia and mild cognitive impairment","author":"Orgeta","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.ncl.2022.05.001_bib34","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/0193945920916750","article-title":"Effects of Mindfulness-based Interventions on Dementia Patients: a meta-analysis","volume":"42","author":"Wang","year":"2020","journal-title":"West J Nurs Res"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/ebmental-2019-300113","article-title":"Treatment for depression comorbid with dementia","volume":"22","author":"Baruch","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.ncl.2022.05.001_bib36","doi-asserted-by":"crossref","first-page":"n532","DOI":"10.1136\/bmj.n532","article-title":"Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis","volume":"372","author":"Watt","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12888-021-03376-y","article-title":"The effects of bright light treatment on affective symptoms in people with dementia: a 24-week cluster randomized controlled trial","volume":"21","author":"Kolberg","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib38","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3233\/JAD-161247","article-title":"Efficacy of antidepressants for depression in Alzheimer\u2019s disease: systematic review and meta-analysis","volume":"58","author":"Orgeta","year":"2017","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.ncl.2022.05.001_bib39","first-page":"CD003944","article-title":"Antidepressants for treating depression in dementia","volume":"8","author":"Dudas","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ncl.2022.05.001_bib40","doi-asserted-by":"crossref","first-page":"101362","DOI":"10.1016\/j.arr.2021.101362","article-title":"Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: A systematic review and meta-analysis","volume":"69","author":"Hsu","year":"2021","journal-title":"Ageing Res Rev"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000077171","article-title":"Frontotemporal dementia: a randomised, controlled trial with trazodone","volume":"17","author":"Lebert","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.ncl.2022.05.001_bib42","article-title":"Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data","volume":"25","author":"Sommerlad","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.001_bib43","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jagp.2019.03.021","article-title":"Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial","volume":"27","author":"Zuidersma","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1099-1166(200004)15:4<295::AID-GPS105>3.0.CO;2-C","article-title":"A\u00a0randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia","volume":"15","author":"Karlsson","year":"2000","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000102570","article-title":"A\u00a0placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia","volume":"24","author":"de Vasconcelos Cunha","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"8","key":"10.1016\/j.ncl.2022.05.001_bib46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4088\/JCP.v64n0804","article-title":"Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents","volume":"64","author":"Oslin","year":"2003","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.14283\/jpad.2019.24","article-title":"Treatment effects of vortioxetine on cognitive functions in mild Alzheimer\u2019s disease patients with depressive symptoms: a 12\u00a0month, open-label, observational study","volume":"6","author":"Cumbo","year":"2019","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib48","doi-asserted-by":"crossref","first-page":"e00461","DOI":"10.1002\/prp2.461","article-title":"Frequency and predictors of the potential overprescribing of antidepressants in elderly residents of a geographically defined U.S. population","volume":"7","author":"Bobo","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib49","first-page":"171","article-title":"The relationship between anxiety and alzheimer\u2019s disease","volume":"5","author":"Mendez","year":"2021","journal-title":"J\u00a0Alzheimers Dis Rep"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib50","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1176\/jnp.15.2.180","article-title":"Frequency and characteristics of anxiety among patients with Alzheimer\u2019s disease and related dementias","volume":"15","author":"Porter","year":"2003","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.ncl.2022.05.001_bib51","doi-asserted-by":"crossref","first-page":"112617","DOI":"10.1016\/j.bbr.2020.112617","article-title":"Non-Pharmacological interventions for the anxiety in patients with dementia. A cross-over randomised controlled trial","volume":"390","author":"Dimitriou","year":"2020","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.ncl.2022.05.001_bib52","first-page":"CD003477","article-title":"Music-based therapeutic interventions for people with dementia","volume":"7","author":"van der Steen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib53","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/WAD.0000000000000454","article-title":"Cognitive behavioral therapy for mood and insomnia in persons with dementia: A systematic review","volume":"35","author":"Jin","year":"2021","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.001_bib54","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1017\/S1041610216002441","article-title":"Buspirone for the treatment of dementia with behavioral disturbance","volume":"29","author":"Santa Cruz","year":"2017","journal-title":"Int Psychogeriatr"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib55","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3233\/JAD-191195","article-title":"Becoming or remaining agitated: the course of agitation in people with dementia living in care homes. The english longitudinal managing agitation and raising quality of life (MARQUE) study","volume":"76","author":"Marston","year":"2020","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1192\/bjp.2019.195","article-title":"The individual course of neuropsychiatric symptoms in people with Alzheimer\u2019s and Lewy body dementia: 12-year longitudinal cohort study","volume":"216","author":"Vik-Mo","year":"2020","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.ncl.2022.05.001_bib57","doi-asserted-by":"crossref","first-page":"103489","DOI":"10.1016\/j.ijnurstu.2019.103489","article-title":"Comparative efficacy of non-pharmacological interventions on agitation in people with dementia: a systematic review and Bayesian network meta-analysis","volume":"102","author":"Leng","year":"2020","journal-title":"Int J Nurs Stud"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.001_bib58","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/M19-0993","article-title":"Comparative efficacy of interventions for aggressive and agitated behaviors in dementia: a systematic review and network meta-analysis","volume":"171","author":"Watt","year":"2019","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.001_bib59","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jagp.2015.05.006","article-title":"Time to response to citalopram treatment for agitation in Alzheimer disease","volume":"23","author":"Weintraub","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.001_bib60","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jamda.2017.06.010","article-title":"Efficacy and safety of citalopram compared to atypical antipsychotics on agitation in nursing home residents with alzheimer dementia","volume":"18","author":"Viscogliosi","year":"2017","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.ncl.2022.05.001_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpsychires.2015.12.005","article-title":"Sedation mediates part of Citalopram\u2019s effect on agitation in Alzheimer\u2019s disease","volume":"74","author":"Newell","year":"2016","journal-title":"J\u00a0Psychiatr Res"},{"issue":"10310","key":"10.1016\/j.ncl.2022.05.001_bib62","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(21)01210-1","article-title":"Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial","volume":"398","author":"Banerjee","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ncl.2022.05.001_bib63","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/ene.14412","article-title":"A\u00a0European Academy of Neurology guideline on medical management issues in dementia","volume":"27","author":"Frederiksen","year":"2020","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib64","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3233\/JAD-200127","article-title":"Real-world treatment patterns and characteristics among patients with agitation and dementia in the United States: findings from a large, observational, retrospective chart review","volume":"77","author":"Aigbogun","year":"2020","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"7","key":"10.1016\/j.ncl.2022.05.001_bib65","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/bcp.13604","article-title":"Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis","volume":"84","author":"Kongpakwattana","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ncl.2022.05.001_bib66","unstructured":"Schedule of Pharmaceutical Benefits, General Pharmaceutical Schedule - Volume 1, published by: Australian Government, Department of Health. Canberra, Commonwealth of Australia.January 2022. Available at: https:\/\/www.pbs.gov.au\/publication\/schedule\/2022\/07\/2022-07-01-general-%20schedule-volume-1.pdf."},{"key":"10.1016\/j.ncl.2022.05.001_bib67","series-title":"Opinion following an article 30 referral for risperdal and associated names","year":"2008"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.001_bib69","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","article-title":"Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses","volume":"15","author":"Mintzer","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.ncl.2022.05.001_bib70","article-title":"Low dose lithium treatment of behavioral complications in Alzheimer\u2019s disease: lit-AD randomized clinical trial","author":"Devanand","year":"2021","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.ncl.2022.05.001_bib71","doi-asserted-by":"crossref","DOI":"10.47626\/2237-6089-2021-0288","article-title":"Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: systematic review","author":"Stella","year":"2021","journal-title":"Trends Psychiatry Psychother"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.001_bib72","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/gps.5381","article-title":"Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer\u2019s disease psychosis: a post hoc analysis","volume":"35","author":"Ballard","year":"2020","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"10.1016\/j.ncl.2022.05.001_bib73","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial","volume":"314","author":"Cummings","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib74","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12877-020-01607-7","article-title":"Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis","volume":"20","author":"Watt","year":"2020","journal-title":"BMC Geriatr"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/ajp.155.1.54","article-title":"Efficacy and tolerability of carbamazepine for agitation and aggression in dementia","volume":"155","author":"Tariot","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib76","doi-asserted-by":"crossref","first-page":"e12157","DOI":"10.1002\/trc2.12157","article-title":"Pharmacological treatment trials of agitation in Alzheimer\u2019s disease: a systematic review of ClinicalTrials.gov registered trials","volume":"7","author":"Liu","year":"2021","journal-title":"Alzheimers Dement (N Y)."},{"issue":"S6","key":"10.1016\/j.ncl.2022.05.001_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/alz.047138","article-title":"The incidence of dementia-related psychosis in people with dementia: Results from a survey of 302\u00a0U.S. healthcare providers","volume":"16","author":"Chen","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.001_bib78","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jagp.2013.01.051","article-title":"Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality","volume":"21","author":"Vilalta-Franch","year":"2013","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.001_bib79","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.001_bib80","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/JCP.0000000000001083","article-title":"Mortality risk of atypical antipsychotics for behavioral and psychological symptoms of dementia: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials","volume":"39","author":"Yeh","year":"2019","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib81","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","article-title":"The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial","volume":"8","author":"Ballard","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2022.05.001_bib82","series-title":"Five things physicians and patients should question","year":"2013"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib84","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.AD19038BR4C","article-title":"Evidence-based treatment and monitoring strategies for dementia-related psychosis","volume":"82","author":"Ballard","year":"2021","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib85","doi-asserted-by":"crossref","first-page":"520","DOI":"10.14283\/jpad.2021.48","article-title":"Comparative efficacy, safety, tolerability, and effectiveness of antipsychotics in the treatment of dementia-related psychosis (DRP): a systematic literature review","volume":"8","author":"Yunusa","year":"2021","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib86","doi-asserted-by":"crossref","first-page":"e190828","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ncl.2022.05.001_bib87","first-page":"CD013304","article-title":"Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia","volume":"12","author":"M\u00fchlbauer","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib88","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib89","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa2034634","article-title":"Trial of Pimavanserin in Dementia-Related Psychosis","volume":"385","author":"Tariot","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ncl.2022.05.001_bib90","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1474-4422(18)30209-6","article-title":"Difficult choices in treating Parkinson\u2019s disease psychosis","volume":"17","year":"2018","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib91","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/brain\/awaa413","article-title":"Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms","volume":"144","author":"Naasan","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2022.05.001_bib92","article-title":"Psychosis management in lewy body dementia: A comprehensive clinical approach","volume":"19","author":"Badwal","year":"2021","journal-title":"J\u00a0Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.ncl.2022.05.001_bib93","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.parkreldis.2020.05.026","article-title":"Treatment of psychosis in Parkinson\u2019s disease and dementia with Lewy Bodies: a review","volume":"75","author":"Kyle","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib94","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","article-title":"New evidence on the management of Lewy body dementia","volume":"19","author":"Taylor","year":"2020","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.001_bib95","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/1533317519853466","article-title":"Apathy and disinhibition related to neuropathology in amnestic versus behavioral dementias","volume":"34","author":"Borges","year":"2019","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.ncl.2022.05.001_bib96","doi-asserted-by":"crossref","first-page":"707799","DOI":"10.3389\/fneur.2021.707799","article-title":"What do we mean by behavioral disinhibition in frontotemporal dementia?","volume":"12","author":"Magrath Guimet","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.ncl.2022.05.001_bib97","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3389\/fphar.2019.01109","article-title":"The hyperactivity-impulsivity-irritiability-disinhibition-aggression-agitation domain in Alzheimer\u2019s disease: current management and future directions","volume":"10","author":"Keszycki","year":"2019","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.ncl.2022.05.001_bib98","first-page":"e18463","article-title":"Treatment and management of sexual disinhibition in elderly patients with neurocognitive disorders","volume":"13","author":"Sarangi","year":"2021","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib99","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jamaneurol.2014.3781","article-title":"Criminal behavior in frontotemporal dementia and Alzheimer disease","volume":"72","author":"Liljegren","year":"2015","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNN.0000000000000217","article-title":"Effectiveness of pharmacological interventions for symptoms of behavioral variant frontotemporal dementia: a systematic review","volume":"33","author":"Trieu","year":"2020","journal-title":"Cogn Behav Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.001_bib101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/WNF.0000000000000469","article-title":"Behavioral and cognitive response to selective serotonin reuptake inhibitors in frontotemporal lobar degeneration: a systematic review and meta-analysis","volume":"44","author":"Nisar","year":"2021","journal-title":"Clin Neuropharmacol"},{"issue":"Pt 7","key":"10.1016\/j.ncl.2022.05.001_bib102","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/brain\/awv133","article-title":"Improving response inhibition systems in frontotemporal dementia with citalopram","volume":"138","author":"Hughes","year":"2015","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib103","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3233\/JAD-150869","article-title":"Classification of neuropsychiatric symptoms requiring antipsychotic treatment in patients with Alzheimer\u2019s disease: analysis of the CATIE-AD study","volume":"50","author":"Nagata","year":"2016","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib104","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40801-015-0047-0","article-title":"Behavioral and Psychological symptoms of dementia and antipsychotic drug use in the elderly with dementia in korean long-term care facilities","volume":"2","author":"Lee","year":"2015","journal-title":"Drugs Real World Outcomes"},{"issue":"6","key":"10.1016\/j.ncl.2022.05.001_bib105","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/psyg.12261","article-title":"A\u00a0case of frontotemporal dementia with sexual disinhibition controlled by aripiprazole","volume":"17","author":"Nomoto","year":"2017","journal-title":"Psychogeriatrics"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib106","first-page":"117","article-title":"Aripiprazole for the Treatment of inappropriate sexual behavior: case report of an Alzheimer\u2019s disease patient known as heterosexual with recently shifted sexual orientation to same gender","volume":"2","author":"Sarikaya","year":"2018","journal-title":"J\u00a0Alzheimers Dis Rep"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib107","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S1041610217000527","article-title":"Prevalence, neurobiology, and treatments for apathy in prodromal dementia","volume":"30","author":"Sherman","year":"2018","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib108","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/WAD.0b013e3182471c54","article-title":"Characterization of apathy in persons with frontotemporal dementia and the impact on family caregivers","volume":"27","author":"Merrilees","year":"2013","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.ncl.2022.05.001_bib109","article-title":"Apathy as a treatment target in alzheimer\u2019s disease: implications for clinical trials","author":"Mortby","year":"2021","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/wvn.12459","article-title":"The effectiveness of non-pharmacological interventions on apathy in patients with dementia: a systematic review of systematic reviews","volume":"17","author":"Cai","year":"2020","journal-title":"Worldviews Evid Based Nurs"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib111","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1002\/gps.4783","article-title":"A\u00a0systematic review of non-pharmacological treatments for apathy in dementia","volume":"33","author":"Theleritis","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.ncl.2022.05.001_bib112","first-page":"CD012197","article-title":"Pharmacological interventions for apathy in Alzheimer\u2019s disease","volume":"5","author":"Ruthirakuhan","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.001_bib113","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2021.3356","article-title":"Effect of methylphenidate on apathy in patients with alzheimer disease: the ADMET 2 randomized clinical trial","volume":"78","author":"Mintzer","year":"2021","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2022.05.001_bib114","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4088\/JCP.10m06708","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer\u2019s disease","volume":"73","author":"Frakey","year":"2012","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib115","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3233\/JAD-200247","article-title":"The efficacy of sertraline, escitalopram, and nicergoline in the treatment of depression and apathy in alzheimer\u2019s disease: the okayama depression and apathy project (ODAP)","volume":"76","author":"Takemoto","year":"2020","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib116","first-page":"1625","article-title":"Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer\u2019s disease: A clinical trial","volume":"17","author":"Zhou","year":"2019","journal-title":"Exp Ther Med"},{"issue":"33","key":"10.1016\/j.ncl.2022.05.001_bib117","doi-asserted-by":"crossref","first-page":"e21497","DOI":"10.1097\/MD.0000000000021497","article-title":"Selective serotonin reuptake inhibitors-associated apathy syndrome: A cross sectional study","volume":"99","author":"Padala","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.001_bib118","doi-asserted-by":"crossref","first-page":"e206027","DOI":"10.1001\/jamanetworkopen.2020.6027","article-title":"Bupropion for the treatment of apathy in alzheimer disease: a randomized clinical trial","volume":"3","author":"Maier","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib119","doi-asserted-by":"crossref","first-page":"e0173872","DOI":"10.1371\/journal.pone.0173872","article-title":"Bupropion for the treatment of apathy in Huntington\u2019s disease: a multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial","volume":"12","author":"Gelderblom","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ncl.2022.05.001_bib120","doi-asserted-by":"crossref","first-page":"e2117573","DOI":"10.1001\/jamanetworkopen.2021.17573","article-title":"Association of Sleep and \u03b2-Amyloid Pathology Among Older Cognitively Unimpaired Adults","volume":"4","author":"Insel","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.ncl.2022.05.001_bib121","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/brain\/awx148","article-title":"Slow wave sleep disruption increases cerebrospinal fluid amyloid-\u03b2 levels","volume":"140","author":"Ju","year":"2017","journal-title":"Brain"},{"issue":"6429","key":"10.1016\/j.ncl.2022.05.001_bib122","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1126\/science.aav2546","article-title":"The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans","volume":"363","author":"Holth","year":"2019","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ncl.2022.05.001_bib123","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jalz.2019.06.3916","article-title":"Profound degeneration of wake-promoting neurons in Alzheimer\u2019s disease","volume":"15","author":"Oh","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib124","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib125","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/07317115.2017.1384777","article-title":"Neuropsychological functioning in older adults with mild cognitive impairment and insomnia randomized to CBT-I or control group","volume":"41","author":"Cassidy-Eagle","year":"2018","journal-title":"Clin Gerontol"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib126","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3233\/JAD-200383","article-title":"Effect of a Multimodal Lifestyle Intervention on Sleep and Cognitive Function in Older Adults with Probable Mild Cognitive Impairment and Poor Sleep: A Randomized Clinical Trial","volume":"76","author":"Falck","year":"2020","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.ncl.2022.05.001_bib128","first-page":"CD009178","article-title":"Pharmacotherapies for sleep disturbances in dementia","volume":"11","author":"McCleery","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib129","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/alz.12035","article-title":"Polysomnographic assessment of suvorexant in patients with probable Alzheimer\u2019s disease dementia and insomnia: a randomized trial","volume":"16","author":"Herring","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ncl.2022.05.001_bib130","first-page":"947","article-title":"Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer\u2019s disease: a 6-month, randomized, placebo-controlled, multicenter trial","volume":"9","author":"Wade","year":"2014","journal-title":"Clin Interv Aging"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib131","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1590\/S0004-282X2011000100010","article-title":"Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study","volume":"69","author":"Camargos","year":"2011","journal-title":"Arq Neuropsiquiatr"},{"issue":"12","key":"10.1016\/j.ncl.2022.05.001_bib132","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jagp.2013.12.174","article-title":"Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study","volume":"22","author":"Camargos","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.001_bib133","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/psyg.12191","article-title":"Mirtazapine does not improve sleep disorders in Alzheimer\u2019s disease: results from a double-blind, placebo-controlled pilot study","volume":"17","author":"Scoralick","year":"2017","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.ncl.2022.05.001_bib134","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12877-016-0196-3","article-title":"Effectiveness of interventions to directly support food and drink intake in people with dementia: systematic review and meta-analysis","volume":"16","author":"Abdelhamid","year":"2016","journal-title":"BMC Geriatr"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/pcn.12375","article-title":"Classifying eating-related problems among institutionalized people with dementia","volume":"70","author":"Shinagawa","year":"2016","journal-title":"Psychiatry Clin Neurosci"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib136","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/jnnp.73.4.371","article-title":"Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer\u2019s disease","volume":"73","author":"Ikeda","year":"2002","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.001_bib137","first-page":"250","article-title":"Predictors of hyperphagia in institutionalized patients with dementia","volume":"22","author":"Wu","year":"2014","journal-title":"J\u00a0Nurs Res"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.001_bib138","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1099800414562025","article-title":"Factors associated with hyperphagic behavior in patients with dementia living at home","volume":"17","author":"Chi","year":"2015","journal-title":"Biol Res Nurs"},{"key":"10.1016\/j.ncl.2022.05.001_bib139","first-page":"707","article-title":"Effectiveness of different memory training programs on improving hyperphagic behaviors of residents with dementia: a longitudinal single-blind study","volume":"11","author":"Kao","year":"2016","journal-title":"Clin Interv Aging"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1479-8301.2012.00429.x","article-title":"Managing abnormal eating behaviours in frontotemporal lobar degeneration patients with topiramate","volume":"13","author":"Shinagawa","year":"2013","journal-title":"Psychogeriatrics"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.001_bib141","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4088\/JCP.v58n0506","article-title":"Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors","volume":"58","author":"Swartz","year":"1997","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"5\u20136","key":"10.1016\/j.ncl.2022.05.001_bib142","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000494210","article-title":"A\u00a0review: mealtime difficulties following frontotemporal lobar degeneration","volume":"46","author":"Lewis","year":"2018","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"10","key":"10.1016\/j.ncl.2022.05.001_bib143","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1212\/01.wnl.0000247630.29222.34","article-title":"Behavioral features in semantic dementia vs other forms of progressive aphasias","volume":"67","author":"Rosen","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.001_bib145","doi-asserted-by":"crossref","first-page":"e2030194","DOI":"10.1001\/jamanetworkopen.2020.30194","article-title":"Progression of behavioral disturbances and neuropsychiatric symptoms in patients with genetic frontotemporal dementia","volume":"4","author":"Benussi","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.001_bib146","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1590\/1980-57642021dn15-030004","article-title":"Treatment of the behavioral variant of frontotemporal dementia: a narrative review","volume":"15","author":"Gambogi","year":"2021","journal-title":"Dement Neuropsychol"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386192200041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386192200041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:21:22Z","timestamp":1760005282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386192200041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":142,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S073386192200041X"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2022.05.001","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Psychiatric Symptoms in Dementia","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2022.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}